138 related articles for article (PubMed ID: 33533945)
1. Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy.
Kramer K; Donzelli MA; Pessin MS
Cancer Immunol Immunother; 2021 Aug; 70(8):2411-2414. PubMed ID: 33533945
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of intraventricular
Kramer K; Pandit-Taskar N; Kushner BH; Zanzonico P; Humm JL; Tomlinson U; Donzelli M; Wolden SL; Haque S; Dunkel I; Souweidane MM; Greenfield JP; Tickoo S; Lewis JS; Lyashchenko SK; Carrasquillo JA; Chu B; Horan C; Larson SM; Cheung NV; Modak S
J Hematol Oncol; 2022 Nov; 15(1):165. PubMed ID: 36371226
[TBL] [Abstract][Full Text] [Related]
3. Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes.
Bailey K; Pandit-Taskar N; Humm JL; Zanzonico P; Gilheeney S; Cheung NV; Kramer K
J Neurooncol; 2019 May; 143(1):101-106. PubMed ID: 30879172
[TBL] [Abstract][Full Text] [Related]
4. B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study.
Modak S; Zanzonico P; Grkovski M; Slotkin EK; Carrasquillo JA; Lyashchenko SK; Lewis JS; Cheung IY; Heaton T; LaQuaglia MP; Cheung NV; Pandit-Taskar N
J Clin Oncol; 2020 Dec; 38(36):4283-4291. PubMed ID: 33119478
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and Dosimetry of Intraventricularly Administered
Pandit-Taskar N; Zanzonico PB; Kramer K; Grkovski M; Fung EK; Shi W; Zhang Z; Lyashchenko SK; Fung AM; Pentlow KS; Carrasquillo JA; Lewis JS; Larson SM; Cheung NV; Humm JL
J Nucl Med; 2019 Dec; 60(12):1794-1801. PubMed ID: 31405921
[TBL] [Abstract][Full Text] [Related]
6. IntraOmmaya compartmental radioimmunotherapy using
Yerrabelli RS; He P; Fung EK; Kramer K; Zanzonico PB; Humm JL; Guo H; Pandit-Taskar N; Larson SM; Cheung NV
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1166-1177. PubMed ID: 33047248
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunoscintigraphy and Pretreatment Dosimetry of
Pandit-Taskar N; Grkovski M; Zanzonico PB; Pentlow KS; Modak S; Kramer K; Humm JL
J Nucl Med; 2023 Jun; 64(6):946-950. PubMed ID: 36759197
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of radioimmunotherapy with intraventricular
Kramer K; Pandit-Taskar N; Humm JL; Zanzonico PB; Haque S; Dunkel IJ; Wolden SL; Donzelli M; Goldman DA; Lewis JS; Lyashchenko SK; Khakoo Y; Carrasquillo JA; Souweidane MM; Greenfield JP; Lyden D; De Braganca KD; Gilheeney SW; Larson SM; Cheung NV
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28940863
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8.
Kramer K; Humm JL; Souweidane MM; Zanzonico PB; Dunkel IJ; Gerald WL; Khakoo Y; Yeh SD; Yeung HW; Finn RD; Wolden SL; Larson SM; Cheung NK
J Clin Oncol; 2007 Dec; 25(34):5465-70. PubMed ID: 18048828
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
[No Abstract] [Full Text] [Related]
11. Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8.
Kramer K; Cheung NK; Humm JL; Dantis E; Finn R; Yeh SJ; Antunes NL; Dunkel IJ; Souwedaine M; Larson SM
Med Pediatr Oncol; 2000 Dec; 35(6):716-8. PubMed ID: 11107154
[TBL] [Abstract][Full Text] [Related]
12. Safety profile of long-term intraventricular access devices in pediatric patients receiving radioimmunotherapy for central nervous system malignancies.
Kramer K; Smith M; Souweidane MM
Pediatr Blood Cancer; 2014 Sep; 61(9):1590-2. PubMed ID: 24777835
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-506 inhibits the proliferation and invasion of mantle cell lymphoma cells by targeting B7H3.
Zhu XW; Wang J; Zhu MX; Wang YF; Yang SY; Ke XY
Biochem Biophys Res Commun; 2019 Jan; 508(4):1067-1073. PubMed ID: 30553455
[TBL] [Abstract][Full Text] [Related]
14. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
15. Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid.
He P; Kramer K; Smith-Jones P; Zanzonico P; Humm J; Larson SM; Cheung NK
Eur J Nucl Med Mol Imaging; 2011 Feb; 38(2):334-42. PubMed ID: 20936407
[TBL] [Abstract][Full Text] [Related]
16. Inhibitor of glutamine metabolism V9302 promotes ROS-induced autophagic degradation of B7H3 to enhance antitumor immunity.
Li Q; Zhong X; Yao W; Yu J; Wang C; Li Z; Lai S; Qu F; Fu X; Huang X; Zhang D; Liu Y; Li H
J Biol Chem; 2022 Apr; 298(4):101753. PubMed ID: 35189139
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas.
Luo L; Qiao H; Meng F; Dong X; Zhou B; Jiang H; Kanwar JR; Krissansen GW; Sun X
Int J Cancer; 2006 Apr; 118(7):1823-30. PubMed ID: 16217749
[TBL] [Abstract][Full Text] [Related]
18. Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma.
Dauer LT; St Germain J; Williamson MJ; Zanzonico P; Modak S; Cheung NK; Divgi C
Health Phys; 2007 Jan; 92(1):33-9. PubMed ID: 17164597
[TBL] [Abstract][Full Text] [Related]
19. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
20. Knocking down B7H3 expression enhances cell proliferation of SHEDs via the SHP1/AKT signal axis.
Chen G; Tu Y; Aladelusi TO; Zhao S; Chen J; Jin L; Zhu D
Biochem Biophys Res Commun; 2020 Oct; 531(3):282-289. PubMed ID: 32800541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
